The total trade value of SCO Member States has increased nearly 100 times over the past 20 years

China's First Oral COVID-19 Antiviral Medicine in Dispute

An obscure Chinese company called Genuine Biotech(Chinese: 真实生物) was suddenly put under the spotlight on July 25 when the Chinese authority announced the conditional approval of the company's application for adding the treatment of COVID-19 as a new indication of Azvudine under the special review and approval procedures for drug registration.

Auto Shanghai 2025 - Nullmax Showcases Full-Stack Automated Driving Solutions

On April 23rd, the biennial Shanghai International Automobile Industry Exhibition kicked off grandly. Nullmax, an AI technology company specializing in AD/ADAS solutions for all scenarios, presented its self-developed full-stack MaxDrive solutions. These solutions range from active safety features to autonomous driving solution for urban scenario based on end-to-end technical architecture, catering to the diverse needs of different vehicle models and markets.

SAIC MAXUS Partners with Huawei Qiankun, Multiple Models to be Launched

On April 23, The 21st Shanghai International Automobile Industry Exhibition (hereinafter referred to as "Auto Shanghai 2025") kicked off, where SAIC Commercial Vehicles unveiled a new strategy to lead the industry's transformation and upgrading. As the core carrier of this strategic upgrade, SAIC MAXUS made its appearance with the theme "Youthful Wealth Creation · Better Life," showcasing multiple wealth-creating new models alongside ecosystem partners, including HUAWEI ADS 4

MANN+HUMMEL Debuts World's First Smoke-Free Explosion-Proof Valve for Power Batteries

MANN+HUMMEL Reshapes New Standard of Safety and Comfort for New Energy Vehicles with Innovative Filtration Technology

Junshi Biosciences Receives NMPA Approval of sNDA for Toripalimab

The study data showed that compared to chemotherapy alone, toripalimab in combination with chemotherapy in the first-line treatment of patients with advanced NSCLC without EGFR/ALK mutations could significantly improve the PFS and the OS of patients with a manageable safety profile regardless of PD-L1 expression status.